CINECA IRIS Institutional Research Information System

MASTORINO, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.752
EU - Europa 1.120
AS - Asia 825
SA - Sud America 102
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 3.827
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.741
IT - Italia 718
SG - Singapore 616
BR - Brasile 95
IE - Irlanda 86
CN - Cina 78
FI - Finlandia 65
SE - Svezia 58
DE - Germania 51
IN - India 44
NL - Olanda 32
HK - Hong Kong 31
FR - Francia 21
GB - Regno Unito 19
NG - Nigeria 16
AT - Austria 11
ID - Indonesia 9
JP - Giappone 9
UA - Ucraina 9
CA - Canada 7
KR - Corea 7
CH - Svizzera 6
MY - Malesia 6
BE - Belgio 5
ES - Italia 5
PL - Polonia 5
RO - Romania 5
EU - Europa 4
IR - Iran 4
LT - Lituania 4
PK - Pakistan 4
AR - Argentina 3
HR - Croazia 3
IQ - Iraq 3
NO - Norvegia 3
TR - Turchia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EE - Estonia 2
HU - Ungheria 2
IL - Israele 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RU - Federazione Russa 2
SI - Slovenia 2
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
KE - Kenya 1
KZ - Kazakistan 1
MK - Macedonia 1
MX - Messico 1
TW - Taiwan 1
VE - Venezuela 1
Totale 3.827
Salva come PNG Salva come JPEG
Città #
Santa Clara 511
Singapore 385
Chandler 287
Turin 110
Milan 104
Columbus 89
Dublin 85
Ashburn 81
Rome 77
Nyköping 45
Helsinki 44
Hong Kong 30
Princeton 24
Medford 22
New York 22
Lappeenranta 21
Guangzhou 17
Abuja 16
Fairfield 14
Falkenstein 14
Hebei 14
Pune 14
Boston 13
Catania 13
Washington 13
Bari 12
Florence 11
Nuremberg 11
Naples 10
Jakarta 8
Munich 8
Torino 8
Venice 8
Beijing 7
Bologna 7
Chengdu 7
Cinisello Balsamo 6
Hangzhou 6
Padova 6
Parma 6
Seattle 6
Brussels 5
Hyderabad 5
Los Angeles 5
Reggio Emilia 5
Seoul 5
Wilmington 5
Brescia 4
Cambridge 4
Cittiglio 4
Covington 4
Faenza 4
Genoa 4
London 4
Mumbai 4
Nellore 4
Norwalk 4
Ottawa 4
The Dalles 4
Amsterdam 3
Brasília 3
Camposampiero 3
Capriolo 3
Castiglione Olona 3
Guiyang 3
Imperatriz 3
Lausanne 3
Lodz 3
Messina 3
Monticello d'Alba 3
Mountain View 3
Oslo 3
Patna 3
Pescara 3
Porto Empedocle 3
Redmond 3
Ribeirão Preto 3
Rio de Janeiro 3
São Paulo 3
Tashkent 3
Urbino 3
Valenzano 3
Vienna 3
Woodbridge 3
Abidjan 2
Ancona 2
Antioch 2
Arcole 2
Arezzo 2
Auckland 2
Belo Horizonte 2
Berlin 2
Boardman 2
Bolligen 2
Bristol 2
Bucharest 2
Bussolengo 2
Cagliari 2
Caivano 2
Casalnuovo di Napoli 2
Totale 2.377
Salva come PNG Salva come JPEG
Nome #
Alopecia areata after COVID-19 vaccination 428
Immunotherapy in Xeroderma Pigmentosum: A case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review 109
Immunotherapy in transplanted patients: A special population that can no longer be ignored 88
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era 72
Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report 70
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 70
Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study 70
Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice 69
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? 69
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 67
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study 66
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study 66
Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications 64
SPECT/CT-Guided Surgical Removal of a Positive External Iliac Sentinel Node in Primary Umbilical Melanoma: Report of a Case, and Up-to-Date Review of the Literature 63
Tocilizumab and its usage for skin diseases 61
Misuse, consequences and phototoxic skin-related effects of Rutaceae: a comprehensive literature review 58
Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review 58
Ruta graveolens phytophotodermatìtis 57
Risankizumab shows high efficacy and maintenance in improvement of response until week 52 56
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population 54
Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related? 53
Clinical outcomes and management of JAK inhibitor-associated acne (JAKne) in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study 52
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis 49
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study 48
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 48
Dupilumab-induced Urticaria 45
Regression of human papillomavirus-associated high-grade vaginal intraepithelial neoplasia after switching from ustekinumab to risankizumab in a psoriasis patient 44
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 42
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma 42
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 41
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 39
593 Inverse psoriasis involvement in moderate to severe psoriatic patients: A comparison between anti IL23 and anti IL17 38
Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case-Control Study 37
Perspectives of immunotherapy in non-melanoma skin cancers 37
Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review 37
Rare scleromyxedema granuloma-annulare-like pattern successfully treated with intravenous immunoglobulins 35
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 34
Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years 34
Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice? 34
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort 33
Lichen ruber planus arising during dupilumab treatment for atopic dermatitis 32
Intraclass Switching among IL17 Inhibitors in Psoriasis: A Real-Life, Long-Term Single-Center Experience 31
Nonmelanoma skin cancer arising on tattoos 31
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 31
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 30
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 30
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis 29
Synchronous occurrence of primary cutaneous B-cell lymphoma and cutaneous Rosai-Dorfman disease in distinct lesions: A unique association 29
Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients 29
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? 28
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 28
A case of treatment-refractory psoriasis as the first manifestation of an HIV-infection 28
Dramatic response of face desmoplastic melanoma after two doses of immunotherapy 28
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis 28
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis 27
Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience 27
Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies 27
Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis 27
Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report 27
Risankizumab-induced red face: a unique presentation 27
A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts 26
Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study 26
Simultaneous Skin Rejuvenation in Patients Undergoing Medical Treatment for Actinic Keratosis and Non-Melanoma Skin Cancer: A Case Series Analysis 25
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study 25
Safety of dupilumab in patients with cancer 23
The Skin Microbiome and Its Role in Psoriasis: A Review 23
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study 23
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience 23
Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single-centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course 23
Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents 22
Comparison of response between adults and adolescents in patients with severe atopic dermatitis treated with dupilumab 22
Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center 22
Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks 22
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study 21
Real-world data on primary cutaneous lymphoproliferative disorders following SARS-CoV-2 vaccination: A multicentre experience from tertiary referral hospitals 21
Exacerbation of acquired perforating dermatosis following SARS-CoV-2 vaccination 21
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study 21
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 20
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study 20
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs 20
Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis over up to 3 years 19
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 18
Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis 18
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 18
Herpes Zoster Infection in Atopic Patients Undergoing Upadacitinib: Practical Suggestions on Vaccination and Management 18
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer 18
Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres 17
'Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'-response to Yu et al 17
Dramatic progression of multifocal primary cutaneous anaplastic large-cell lymphoma 15
Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics 15
Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study 15
The limitation of accessing hospital services due to COVID-19 pandemic: a pilot study of the telephone triage to re-organize the access to a Center for Sexual Health in North-West Italy 15
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 15
Alcohol abuse and discretionary habits in psoriatic patients: impact on IL‐17 and IL‐23 inhibitors response 15
Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study 15
Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis 15
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 15
Secondary laryngeal and pulmonary syphilis: A case report 14
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk 14
Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents 14
Totale 3.880
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 2 4
2021/2022311 36 7 6 13 45 17 5 4 10 6 44 118
2022/2023803 55 92 15 58 70 128 36 119 64 18 107 41
2023/2024704 60 104 45 52 33 101 38 43 11 54 45 118
2024/20252.186 42 217 81 202 779 195 80 126 283 181 0 0
Totale 4.010